Literature DB >> 34373941

Prognostic impact of splenic vessel involvement and tumor size in distal pancreatectomy for adenocarcinoma: a retrospective multicentric cohort study.

Dominique Gantois1, Théophile Guilbaud1, Ugo Scemama2, Edouard Girard3, Olivier Picaud1, Marine Lefevre4, Myriam Elgani5, Zeinab Hamidou6, Vincent Moutardier1, Paul Balandraud7, Mircea Chirica3, Louise Barbier8, David Fuks9, David Jérémie Birnbaum10.   

Abstract

PURPOSE: Splenic vessel involvement occurs frequently in pancreatic ductal adenocarcinoma (PDAC) of the body and the tail (B/T) but the impact on survival is unknown. We assessed the influence of radiological and pathologic involvement of splenic artery (p-SA +) and vein (p-SV +) on patient outcomes after distal pancreatectomy (DP) for PDAC.
METHODS: From 2013 to 2019, all DP for PDAC in five centers were included. Factors associated with overall (OS) and disease-free (DFS) survival were identified.
RESULTS: Among the 76 patients included, 5 (6.6%) had p-SA + only, 11 (14.5%) had p-SV + only, and 24 (31.6%) had both p-SA + and p-SV + . The preoperative CT-scan accuracy to predict p-SV + and p-SA + was high (sensitivity: 91.4% and 82.8%, respectively; negative predictive value: 89.7% and 88.3%, respectively). The 5-year OS and DFS rates were 3.9% and 8.3%, respectively. Multivariate analysis identified splenic vessel involvement (i.e., p-SA + or p-SV + , or both p-SA + and p-SV +) as the only independent factor influencing DFS (HR 4.04; 95% CI [1.22-13.44], p = 0.023). Tumor size ≥ 30 mm was the only independent factor influencing OS (HR 4.04; 95% CI [1.26-12.95], p = 0.019) and was associated with a high risk of p-SA + (p = 0.001) and p-SV + (p < 0.001).
CONCLUSION: Tumor size ≥ 30 mm and splenic vessel involvement occurred in more than half of the patients who underwent DP for PDAC and had negative impact on long-term survival. Preoperative CT-scan was reliable to identify splenic vessel involvement in B/T PDAC. Large tumor size and radiological splenic vessel involvement could be taken into account to propose a neoadjuvant treatment.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Distal pancreatectomy; Long-term survival; Pancreatic ductal adenocarcinoma; Prognosis; Splenic vessel involvement

Mesh:

Year:  2021        PMID: 34373941     DOI: 10.1007/s00423-021-02291-w

Source DB:  PubMed          Journal:  Langenbecks Arch Surg        ISSN: 1435-2443            Impact factor:   2.895


  33 in total

1.  Management of adenocarcinoma of the body and tail of the pancreas.

Authors:  M F Brennan; R D Moccia; D Klimstra
Journal:  Ann Surg       Date:  1996-05       Impact factor: 12.969

2.  Outcomes after resection of locally advanced or borderline resectable pancreatic cancer after neoadjuvant therapy.

Authors:  Giuliano Barugola; Stefano Partelli; Stefano Crippa; Paola Capelli; Mirko D'Onofrio; Paolo Pederzoli; Massimo Falconi
Journal:  Am J Surg       Date:  2011-08-06       Impact factor: 2.565

3.  Preoperative Therapy and Pancreatoduodenectomy for Pancreatic Ductal Adenocarcinoma: a 25-Year Single-Institution Experience.

Authors:  Jordan M Cloyd; Matthew H G Katz; Laura Prakash; Gauri R Varadhachary; Robert A Wolff; Rachna T Shroff; Milind Javle; David Fogelman; Michael Overman; Christopher H Crane; Eugene J Koay; Prajnan Das; Sunil Krishnan; Bruce D Minsky; Jeffrey H Lee; Manoop S Bhutani; Brian Weston; William Ross; Priya Bhosale; Eric P Tamm; Huamin Wang; Anirban Maitra; Michael P Kim; Thomas A Aloia; Jean-Nicholas Vauthey; Jason B Fleming; James L Abbruzzese; Peter W T Pisters; Douglas B Evans; Jeffrey E Lee
Journal:  J Gastrointest Surg       Date:  2016-10-24       Impact factor: 3.452

4.  The impact of splenectomy on outcomes after resection of pancreatic adenocarcinoma.

Authors:  R E Schwarz; L E Harrison; K C Conlon; D S Klimstra; M F Brennan
Journal:  J Am Coll Surg       Date:  1999-05       Impact factor: 6.113

5.  More deaths from pancreatic cancer than breast cancer in the EU by 2017.

Authors:  J Ferlay; C Partensky; F Bray
Journal:  Acta Oncol       Date:  2016-08-23       Impact factor: 4.089

6.  Distal pancreatectomy for pancreatic carcinoma in the era of multimodal treatment.

Authors:  F Paye; R Micelli Lupinacci; P Bachellier; J-M Boher; J-R Delpero
Journal:  Br J Surg       Date:  2014-12-22       Impact factor: 6.939

7.  Pancreatic cancer: a report of treatment and survival trends for 100,313 patients diagnosed from 1985-1995, using the National Cancer Database.

Authors:  S F Sener; A Fremgen; H R Menck; D P Winchester
Journal:  J Am Coll Surg       Date:  1999-07       Impact factor: 6.113

8.  Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer.

Authors:  Cristina R Ferrone; Giovanni Marchegiani; Theodore S Hong; David P Ryan; Vikram Deshpande; Erin I McDonnell; Francesco Sabbatino; Daniela Dias Santos; Jill N Allen; Lawrence S Blaszkowsky; Jeffrey W Clark; Jason E Faris; Lipika Goyal; Eunice L Kwak; Janet E Murphy; David T Ting; Jennifer Y Wo; Andrew X Zhu; Andrew L Warshaw; Keith D Lillemoe; Carlos Fernández-del Castillo
Journal:  Ann Surg       Date:  2015-01       Impact factor: 12.969

9.  Curative resection is the single most important factor determining outcome in patients with pancreatic adenocarcinoma.

Authors:  M Wagner; C Redaelli; M Lietz; C A Seiler; H Friess; M W Büchler
Journal:  Br J Surg       Date:  2004-05       Impact factor: 6.939

10.  Evaluation of the prognostic factors and significance of lymph node status in invasive ductal carcinoma of the body or tail of the pancreas.

Authors:  Takeo Fujita; Toshio Nakagohri; Naoto Gotohda; Shinichiro Takahashi; Masaru Konishi; Motohiro Kojima; Taira Kinoshita
Journal:  Pancreas       Date:  2010-01       Impact factor: 3.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.